The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review.

IF 1.6 Q4 ONCOLOGY

Journal of Gastrointestinal Cancer Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI:10.1007/s12029-024-01078-8

Zouina Sarfraz, Azza Sarfraz, Muhammad Danyal Farooq, Musfira Khalid, Khadija Cheema, Faheem Javad, Taleah Khan, Zainab Pervaiz, Muzna Sarfraz, Ali Jaan, Subhan Sadiq, Junaid Anwar

{"title":"The Current Landscape of Clinical Trials for Immunotherapy in Pancreatic Cancer: A State-of-the-Art Review.","authors":"Zouina Sarfraz, Azza Sarfraz, Muhammad Danyal Farooq, Musfira Khalid, Khadija Cheema, Faheem Javad, Taleah Khan, Zainab Pervaiz, Muzna Sarfraz, Ali Jaan, Subhan Sadiq, Junaid Anwar","doi":"10.1007/s12029-024-01078-8","DOIUrl":null,"url":null,"abstract":"Background: Pancreatic cancer remains a lethal malignancy with a 5-year survival rate below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the most prevalent form, is commonly associated with diabetes, chronic pancreatitis, obesity, and smoking, mainly affecting individuals aged 60 to 80 years. This systematic review aims to evaluate the efficacy of immunotherapeutic approaches in the treatment of pancreatic cancer.Methods: A systematic search was conducted to identify clinical trials (Phases I-III) assessing immunotherapy in pancreatic cancer in PubMed/Medline, CINAHL, Scopus, and Web of Science, adhering to PRISMA Statement 2020 guidelines. The final search was completed on May 25, 2024. Ongoing trials were sourced from ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Keywords such as \"pancreatic,\" \"immunotherapy,\" \"cancer,\" and \"clinical trial\" were used across databases. Gray literature was excluded.Results: Phase I trials, involving 337 patients, reported a median overall survival (OS) of 13.6 months (IQR: 5-62.5 months) and a median progression-free survival (PFS) of 5.1 months (IQR: 1.9-11.7 months). Phase II/III trials pooled in a total of 1463 participants had a median OS of 12.2 months (IQR: 2.5-35.55 months) and a median PFS of 8.8 months (IQR: 1.4-33.51 months).Conclusions: Immunotherapy shows potential for extending survival among pancreatic cancer patients, though results vary. The immunosuppressive nature of the tumor microenvironment and diverse patient responses underline the need for further research to optimize these therapeutic strategies.","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-024-01078-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Pancreatic cancer remains a lethal malignancy with a 5-year survival rate below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the most prevalent form, is commonly associated with diabetes, chronic pancreatitis, obesity, and smoking, mainly affecting individuals aged 60 to 80 years. This systematic review aims to evaluate the efficacy of immunotherapeutic approaches in the treatment of pancreatic cancer.

Methods: A systematic search was conducted to identify clinical trials (Phases I-III) assessing immunotherapy in pancreatic cancer in PubMed/Medline, CINAHL, Scopus, and Web of Science, adhering to PRISMA Statement 2020 guidelines. The final search was completed on May 25, 2024. Ongoing trials were sourced from ClinicalTrials.gov and the World Health Organization's International Clinical Trials Registry Platform (ICTRP). Keywords such as "pancreatic," "immunotherapy," "cancer," and "clinical trial" were used across databases. Gray literature was excluded.

Results: Phase I trials, involving 337 patients, reported a median overall survival (OS) of 13.6 months (IQR: 5-62.5 months) and a median progression-free survival (PFS) of 5.1 months (IQR: 1.9-11.7 months). Phase II/III trials pooled in a total of 1463 participants had a median OS of 12.2 months (IQR: 2.5-35.55 months) and a median PFS of 8.8 months (IQR: 1.4-33.51 months).

Conclusions: Immunotherapy shows potential for extending survival among pancreatic cancer patients, though results vary. The immunosuppressive nature of the tumor microenvironment and diverse patient responses underline the need for further research to optimize these therapeutic strategies.

查看原文本刊更多论文

胰腺癌免疫疗法临床试验的现状：最新研究综述

背景：胰腺癌仍然是一种致命的恶性肿瘤，5 年生存率低于 6%，全球每年约有 50 万人死于此病。胰腺癌是发病率最高的癌症，通常与糖尿病、慢性胰腺炎、肥胖和吸烟有关，主要影响 60 至 80 岁的人群。本系统综述旨在评估免疫治疗方法在治疗胰腺癌方面的疗效：方法：根据 PRISMA Statement 2020 指南，对 PubMed/Medline、CINAHL、Scopus 和 Web of Science 中评估胰腺癌免疫疗法的临床试验（I-III 期）进行了系统检索。最终搜索于 2024 年 5 月 25 日完成。正在进行的试验来自 ClinicalTrials.gov 和世界卫生组织的国际临床试验注册平台 (ICTRP)。各数据库均使用了 "胰腺"、"免疫疗法"、"癌症 "和 "临床试验 "等关键词。灰色文献被排除在外：I 期试验涉及 337 名患者，中位总生存期 (OS) 为 13.6 个月（IQR：5-62.5 个月），中位无进展生存期 (PFS) 为 5.1 个月（IQR：1.9-11.7 个月）。II/III期试验共汇集了1463名参与者，中位OS为12.2个月（IQR：2.5-35.55个月），中位PFS为8.8个月（IQR：1.4-33.51个月）：免疫疗法具有延长胰腺癌患者生存期的潜力，但结果各不相同。肿瘤微环境的免疫抑制性质和患者的不同反应强调了进一步研究优化这些治疗策略的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Gastrointestinal Cancer ONCOLOGY-

CiteScore

3.80

自引率

0.00%

发文量

121

期刊介绍： The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.